FutureCast | Time to Reboot Biotech

FinanceBiotech
Written By Chris Morrison
 

Featuring Raj Shah, Jake Simson, Tess Cameron, and Peter Kolchinsky

On RApport's FutureCast, the RA Capital team discusses how today's technology and policy trends could improve health and life on Earth for generations to come.

February 9, 2023

RApport’s FutureCast returned yesterday with a vibrant roundtable discussion about the health of the biotech industry and prospects for a recovery from the last two brutal years. 

If any of that sounds familiar, you might have already read the “Time to Reboot Biotech” article that we published just before the JPM conference. We wanted to give one of our most widely-read pieces some air time with a few hundred of our subscribers - who as you’ll see, weren’t shy about chiming in during the discussion (sadly the replay won’t show the constant Q&A taking place in the live-chat).

The panel also previewed one more financial analysis we just completed that contradicts a recently emerging conventional view of how to look for signals of a recovery. (It’s not in the Reboot article - but we’ll get to it, so stay tuned!)

Please click here for important RA Capital disclosures.

Related reading

Featured
Semper Maior: Reflecting on a quiet 1H24
Semper Maior, sector trends, Peter Kolchinsky, Financing, M&A, IPO, Investing, investors
Finance, Biotech
Semper Maior: Reflecting on a quiet 1H24
Semper Maior, sector trends, Peter Kolchinsky, Financing, M&A, IPO, Investing, investors
Finance, Biotech

Our usual top-down biotech sector metrics showed that 1H24 was… pretty boring (though for us bottom-up folks, individual companies offer plenty of excitement). After the last few years, boring ain’t bad. With expectations of Fed easing interest rates due to waning inflation, the excitement level for the second half of the year has already picked up, but that’s not reflected in the metrics here.

Semper Maior, sector trends, Peter Kolchinsky, Financing, M&A, IPO, Investing, investors
Finance, Biotech
Semper Maior: Time to Reboot Biotech
M&A, IPO, Reverse Merger, RA Capital Author, Downturn, Generalized Cost Effectiveness Analysis, efficiency, Series I, Semper Maior
Finance, Biotech
Semper Maior: Time to Reboot Biotech
M&A, IPO, Reverse Merger, RA Capital Author, Downturn, Generalized Cost Effectiveness Analysis, efficiency, Series I, Semper Maior
Finance, Biotech

We’ve suffered a protracted downturn in general interest in biotech. That downturn has been compounded by rising interest rates undercutting equities in general. Now we must determine 1) how much worse this downturn might be and 2) how we’ll do things differently once we reboot. Here, Peter Kolchinsky explains why he believes we’ve emerged from the downturn but must reboot biotech with more honest and efficient processes and better defend our industry’s value proposition to policymakers and the public.

M&A, IPO, Reverse Merger, RA Capital Author, Downturn, Generalized Cost Effectiveness Analysis, efficiency, Series I, Semper Maior
Finance, Biotech
Saving money for Medicare by abandoning new drugs for Medicare patients
Reforms, R&D, competition, innovation, IRA, Congress, Arizona, investors, incentives, cancer
Policy, Finance, Biotech
Saving money for Medicare by abandoning new drugs for Medicare patients
Reforms, R&D, competition, innovation, IRA, Congress, Arizona, investors, incentives, cancer
Policy, Finance, Biotech

As the founder of two biotech companies in Arizona that are currently fundraising to support drug development, it’s clear to me that the Inflation Reduction Act will steer me away from developing cancer drugs for older Americans. This is a problem that can be fixed.

Reforms, R&D, competition, innovation, IRA, Congress, Arizona, investors, incentives, cancer
Policy, Finance, Biotech
Chris Morrison
Previous

A crisis we don’t need: How not to cause a bank run
Next

So you want to be a TechAtlas intern…